Izrael - angleščina - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Izrael - angleščina - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Izrael - angleščina - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml - solution for injection - 100 mcg/ml - active: octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml - solution for injection - 50 mcg/ml - active: octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

max health limited - octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml - solution for injection - 500 mcg/ml - active: octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 100 microgram(s)/millilitre - somatostatin and analogues; octreotide

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 200 microgram(s)/millilitre - somatostatin and analogues; octreotide

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 50 microgram(s)/millilitre - somatostatin and analogues; octreotide

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - octreotide acetate - solution for injection - 500 microgram(s)/millilitre - somatostatin and analogues; octreotide